KB301

· Krystal Biotech, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KB301, covering 2025-05-13 to 2025-05-13. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions [Phase 1]

See pricing